Hematology Oncology and Stem Cell Therapy This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Acute myeloid leukemia in a patient with thrombocytopenia with absent radii: A case report and review of the literature
We report a case of myelodysplastic syndrome progressing to AML with calreticulin driver mutation in an adult male with TAR syndrome who was successfully treated with hematopoietic allogeneic stem cell transplantation. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Waldenström’s macroglobulinemia masquerading as ovarian cancer with peritoneal carcinomatosis, ascites, and elevated CA-125
Publication date: Available online 31 March 2017Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Patrick Eulitt, Denise Fabian, Crystal Kelly, Jessica Hemminger, Basem M. WilliamAbstractWaldenström’s macroglobulinemia is a rare hematology malignancy which often presents with “B symptoms,” anemia, and thrombocytopenia. A 46-year-old woman presented with 2 months of abdominal distension accompanied by an unintentional 20-lb weight loss. Her abdominal CT scan demonstrated diffuse carcinomatosis with bilateral ovarian lesions and screening labs revealed a markedly elevated CA-125, suggesting a diagnosis of ov...
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Myasthenia gravis after allogeneic bone marrow transplantation: A case report and literature review
Publication date: Available online 18 May 2017Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Yutaka Tsutsumi, Takashi Kamiishi, Ryo Kikuchi, Shinichi Ito, Satomi Matsuoka, Takanori TeshimaAbstractA 52-year-old man with acute myeloid leukemia underwent allogeneic hematopoietic stem cell transplantation and developed extensive chronic graft-versus-host disease and myasthenia gravis (MG), which became involved with oculobulbar and proximal upper and lower limb weakness in 677 days. In the literature, we identified 24 cases where MG developed after allo-SCT. Graft-versus-host disease development and male reci...
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report
We describe a case of secondary HLH that did not respond favorably to conventional treatments. Serum inflammatory markers continued to rise significantly with clinical deterioration and worsening pancytopenia. The severe thrombocytopenia and neutropenia were deemed to have contributed to a spontaneous subdural hematoma and candidemia, respectively. Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, was then utilized as a novel salvage therapy based on available in vivo murine data at the time. Following initiation, there was improvement seen in several disease markers, including serum ferritin, lactate dehydrogenase, fibrino...
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia—A case report
Publication date: Available online 16 August 2017Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Prajwal Boddu, Ellen Schlette, Beenu Thakral, Guillin Tang, Naveen Pemmaraju, Tapan Kadia, Alessandra Ferrajoli, Farhad Ravandi, William Wierda, Nitin JainAbstractChronic lymphocytic leukemia (CLL) is known to be associated rarely with myeloid malignancies such as acute myelogenous leukemia. In this article, we report an extremely rare occurrence of acute promyelocytic leukemia in a patient with CLL. A 71-year-old man first presented to our clinic with a diagnosis of CLL and worsening motor neuropathy symptoms. It w...
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Thrombo-hemorrhagic liability in children with congenital heart diseases
ConclusionPatients with CHD—both cyanotic and acyanotic—have variable degrees of increased liability for both thrombosis and hemorrhage that represents some sort of adaptation to preserve hemostasis and to protect these patients against the clinical presentation of both thrombosis and bleeding. This is to say that CHD patients have their own point of balance between thrombogenicity and bleeding liability. Wide-scale studies are needed to detect the normal levels of different thrombohemorrhagic parameters of these patients. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Hereditary persistence of hemoglobin F is protective against red cell sickling. A case report and brief review
We describe a case of SCD, in which a patient with high HbF level presented at a very late age (27 years old). We presume the patient’s inherently elevated HbF levels were able to compensate for the hypoxic episodes associated with SCD. The onset of symptoms was delayed as a result of elevated HbF levels. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Double CD38−/CD138− negative multiple myeloma
We present an unusual case of CD138− negative multiple myeloma which had become double CD138−/CD38− negative after treatment with daratumumab by which we would like to illustrate potential pitfalls of both strategies. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Aging and stem cell therapy: AMPK as an applicable pharmacological target for rejuvenation of aged stem cells and achieving higher efficacy in stem cell therapy
Publication date: Available online 19 October 2017Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Mohammadhossein Khorraminejad-Shirazi, Mohammad Farahmandnia, Bahareh Kardeh, Alireza Estedlal, Sina Kardeh, Ahmad MonabatiAbstractIn recent years, tissue regeneration has become a promising field for developing stem cell-based transplantation therapies for human patients. Adult stem cells are affected by the same aging mechanisms that involve somatic cells. One of the mechanisms involved in cellular aging is hyperactivation of mechanistic target of rapamycin complex 1 (mTORC1) and disruption of 5′ adenosine mono...
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Co-existence of myeloid neoplasm and monoclonal gammopathy; case series and review of literature
Publication date: Available online 6 December 2017Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Navkirti Mittal, Ruchi Gupta, Khaliqur Rahman, Tanvi Gupta, Soniya Nityanand (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Utility of routine surveillance imaging for diffuse large B-cell lymphoma post autologous transplant: A single center experience
Publication date: Available online 19 December 2017Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Ghulam Rehman Mohyuddin, Ashley Elizabeth Clark, John Roller, Leyla Shune, Tara Lin, Neil Dunavin, Ajoy Dias, Siddhartha Ganguly, Sunil Abhyankar, Joseph McGuirk, Anurag SinghAbstractSurveillance scans after autologous stem cell transplant (auto-HCT) for patients with relapsed/refractory (RR) diffuse large B Cell lymphoma (DLBCL) have no proven survival benefit. We studied survival differences among patients with RR DLBCL post auto-HCT whose recurrences were detected clinically versus with routine surveillance ima...
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Acquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation
We report a patient with thymoma complicated by pure red cell aplasia (PRCA) and AAMT who progressed to develop aplastic anemia (AA). The patient was refractory to 10-months of immunosuppressive therapy with cyclosporine, prednisone, and antithymocyte globulin. She was eventually treated with allogeneic stem cell transplantation (allo-SCT). On Day +323 the patient continues to be transfusion-independent. This case illustrates how in patients with thymoma and AAMT may herald development of AA. This is also the first report of a patient with AAMT progressing to thymoma-associated AA being successfully treated with allo-SCT. ...
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Coagulopathic side effect of L-asparaginase on fibrinogen level in childhood acute lymphoblastic leukemia during induction phase
ConclusionSignificant reduction in fibrinogen level occurred in childhood ALL patients after treatment with L-asparaginase. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Fecal calprotectin and serum albumin as markers of gastrointestinal graft versus host disease
ConclusionPatients with steroid-refractory GI aGVHD had higher fecal calprotectin levels and lower albumin levels than patients with steroid-responsive disease. We recommend further studies to evaluate non-invasive tests with fecal calprotectin in combination with albumin in predicting steroid refractory disease at onset of symptoms to potentially identify patients that may benefit from upfront escalation in GVHD treatment. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research

Ibritumomab tiuxetan (Zevalin) and elevated serum human anti-murine antibody (HAMA)
Publication date: Available online 1 February 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Sarbajit Mukherjee, Adanma Ayanambakkam, Sami Ibrahimi, Sarah Schmidt, Jennifer Holter Charkrabarty, Mohamad KhawandanahAbstractIbritumomab Tiuxetan (Zevalin) is an anti CD-20 murine monoclonal antibody linked to the radio-isotope 90-yttrium (90Y) by the chelator Tiuxetan. It is FDA approved for treatment of relapsed low grade or follicular B-cell Non-Hodgkin's Lymphoma (NHL) or newly diagnosed follicular NHL following an initial response to first-line chemotherapy. Patients may develop Human Anti-Murine Antibodies...
Source: Hematology Oncology and Stem Cell Therapy - July 5, 2018 Category: Cancer & Oncology Source Type: research